Safety of the combination of valsartan and benazepril in patients with chronic renal disease

Luis M. Ruilope, Jean C. Aldigier, Claudio Ponticelli, Pascale Oddou-Stock, Florence Botteri, Johannes F. Mann

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Objective. Several experimental and clinical studies indicate that the renin system may play a pivotal role in progressing renal disease. The combination of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker could provide a higher degree of blockade of the renin-angiotensin system than either agent alone. Such enhanced suppression might be of benefit for patients exhibiting a progressive decline in renal function because of chronic renal disease. Methods. A pilot multinational, multicentre, randomized, active-controlled, parallel group open-label study has been conducted in a group of patients with progressive chronic renal failure (creatinine clearance 20-45 ml/min) either with or without proteinuria and hypertension. The primary aim of the study was to investigate the safety and tolerability of the combination of valsartan and benazepril. Patients were randomly assigned to one of three groups: group 1 received valsartan 160 mg once daily (n = 22); group 2 received valsartan 80 mg once daily plus benazepril 5 or 10 mg once daily (n = 42); group 3 received valsartan 160 mg once daily plus benazepril 5 or 10 mg once daily (n = 44). The study lasted for 5 weeks, and in groups 2 and 3 benazepril was added on top of valsartan after the first week of therapy with the angiotensin receptor blocker. Results. Serum creatinine increased in all three groups (mean change within a group: 11 μmol/l in group 1, P = 0.045; 9 μmol/l in group 2, P = 0.030; 15 μmol/l in group 3, P = 0.0006). Serum potassium also increased in all three groups of patients (mean change within a group: 0.28 mmol/l in group 1, P = 0.28; 0.48 mmol/l in group 2, P = 0.0008; 0.36 mmol/l in group 3, P = 0.02). After 5 weeks of treatment, the largest decrease in blood pressure was observed in group 3 (the mean change from baseline in seated diastolic blood pressure (SDBP) and seated systolic blood pressure (SSBP), respectively, were: -2.0 and -11.5 mmHg in group 1; -7.6 and -15.4 mmHg in group 2; -12.6 and -21.6 mmHg in group 3). In addition, both combination treatments resulted in the reduction of proteinuria. The total number of patients with adverse experiences were 10 (45.5%), 14 (33.3%) and 11 (25%) in groups 1, 2 and 3, respectively. In six patients (5.6%) therapy was discontinued as a result of adverse experiences. Only one patient in each of the combined therapy groups withdrew from the study because of hyperkalaemia and no patients were forced to withdraw because of an increase in serum creatinine, acute renal failure or hospitalization. Conclusions. These results indicate that short-term combination of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker is safe and well tolerated in patients with moderate chronic renal failure. (C) Lippincott Williams and Wilkins.

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalJournal of Hypertension
Volume18
Issue number1
Publication statusPublished - 2000

Fingerprint

Valsartan
Chronic Renal Insufficiency
Safety
Angiotensin Receptor Antagonists
Blood Pressure
Creatinine
Proteinuria
Angiotensin-Converting Enzyme Inhibitors
Chronic Kidney Failure
Serum
Kidney
benazepril
Hyperkalemia
Therapeutics
Renin-Angiotensin System
Group Psychotherapy

Keywords

  • Angiotensin converting enzyme inhibition
  • Angiotensin type 1 receptor antagonists
  • Benazepril
  • Combination therapy
  • Valsartan

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Cite this

Ruilope, L. M., Aldigier, J. C., Ponticelli, C., Oddou-Stock, P., Botteri, F., & Mann, J. F. (2000). Safety of the combination of valsartan and benazepril in patients with chronic renal disease. Journal of Hypertension, 18(1), 89-95.

Safety of the combination of valsartan and benazepril in patients with chronic renal disease. / Ruilope, Luis M.; Aldigier, Jean C.; Ponticelli, Claudio; Oddou-Stock, Pascale; Botteri, Florence; Mann, Johannes F.

In: Journal of Hypertension, Vol. 18, No. 1, 2000, p. 89-95.

Research output: Contribution to journalArticle

Ruilope, LM, Aldigier, JC, Ponticelli, C, Oddou-Stock, P, Botteri, F & Mann, JF 2000, 'Safety of the combination of valsartan and benazepril in patients with chronic renal disease', Journal of Hypertension, vol. 18, no. 1, pp. 89-95.
Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. Journal of Hypertension. 2000;18(1):89-95.
Ruilope, Luis M. ; Aldigier, Jean C. ; Ponticelli, Claudio ; Oddou-Stock, Pascale ; Botteri, Florence ; Mann, Johannes F. / Safety of the combination of valsartan and benazepril in patients with chronic renal disease. In: Journal of Hypertension. 2000 ; Vol. 18, No. 1. pp. 89-95.
@article{c1f8002da929465c8590a552e3f28f1f,
title = "Safety of the combination of valsartan and benazepril in patients with chronic renal disease",
abstract = "Objective. Several experimental and clinical studies indicate that the renin system may play a pivotal role in progressing renal disease. The combination of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker could provide a higher degree of blockade of the renin-angiotensin system than either agent alone. Such enhanced suppression might be of benefit for patients exhibiting a progressive decline in renal function because of chronic renal disease. Methods. A pilot multinational, multicentre, randomized, active-controlled, parallel group open-label study has been conducted in a group of patients with progressive chronic renal failure (creatinine clearance 20-45 ml/min) either with or without proteinuria and hypertension. The primary aim of the study was to investigate the safety and tolerability of the combination of valsartan and benazepril. Patients were randomly assigned to one of three groups: group 1 received valsartan 160 mg once daily (n = 22); group 2 received valsartan 80 mg once daily plus benazepril 5 or 10 mg once daily (n = 42); group 3 received valsartan 160 mg once daily plus benazepril 5 or 10 mg once daily (n = 44). The study lasted for 5 weeks, and in groups 2 and 3 benazepril was added on top of valsartan after the first week of therapy with the angiotensin receptor blocker. Results. Serum creatinine increased in all three groups (mean change within a group: 11 μmol/l in group 1, P = 0.045; 9 μmol/l in group 2, P = 0.030; 15 μmol/l in group 3, P = 0.0006). Serum potassium also increased in all three groups of patients (mean change within a group: 0.28 mmol/l in group 1, P = 0.28; 0.48 mmol/l in group 2, P = 0.0008; 0.36 mmol/l in group 3, P = 0.02). After 5 weeks of treatment, the largest decrease in blood pressure was observed in group 3 (the mean change from baseline in seated diastolic blood pressure (SDBP) and seated systolic blood pressure (SSBP), respectively, were: -2.0 and -11.5 mmHg in group 1; -7.6 and -15.4 mmHg in group 2; -12.6 and -21.6 mmHg in group 3). In addition, both combination treatments resulted in the reduction of proteinuria. The total number of patients with adverse experiences were 10 (45.5{\%}), 14 (33.3{\%}) and 11 (25{\%}) in groups 1, 2 and 3, respectively. In six patients (5.6{\%}) therapy was discontinued as a result of adverse experiences. Only one patient in each of the combined therapy groups withdrew from the study because of hyperkalaemia and no patients were forced to withdraw because of an increase in serum creatinine, acute renal failure or hospitalization. Conclusions. These results indicate that short-term combination of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker is safe and well tolerated in patients with moderate chronic renal failure. (C) Lippincott Williams and Wilkins.",
keywords = "Angiotensin converting enzyme inhibition, Angiotensin type 1 receptor antagonists, Benazepril, Combination therapy, Valsartan",
author = "Ruilope, {Luis M.} and Aldigier, {Jean C.} and Claudio Ponticelli and Pascale Oddou-Stock and Florence Botteri and Mann, {Johannes F.}",
year = "2000",
language = "English",
volume = "18",
pages = "89--95",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Safety of the combination of valsartan and benazepril in patients with chronic renal disease

AU - Ruilope, Luis M.

AU - Aldigier, Jean C.

AU - Ponticelli, Claudio

AU - Oddou-Stock, Pascale

AU - Botteri, Florence

AU - Mann, Johannes F.

PY - 2000

Y1 - 2000

N2 - Objective. Several experimental and clinical studies indicate that the renin system may play a pivotal role in progressing renal disease. The combination of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker could provide a higher degree of blockade of the renin-angiotensin system than either agent alone. Such enhanced suppression might be of benefit for patients exhibiting a progressive decline in renal function because of chronic renal disease. Methods. A pilot multinational, multicentre, randomized, active-controlled, parallel group open-label study has been conducted in a group of patients with progressive chronic renal failure (creatinine clearance 20-45 ml/min) either with or without proteinuria and hypertension. The primary aim of the study was to investigate the safety and tolerability of the combination of valsartan and benazepril. Patients were randomly assigned to one of three groups: group 1 received valsartan 160 mg once daily (n = 22); group 2 received valsartan 80 mg once daily plus benazepril 5 or 10 mg once daily (n = 42); group 3 received valsartan 160 mg once daily plus benazepril 5 or 10 mg once daily (n = 44). The study lasted for 5 weeks, and in groups 2 and 3 benazepril was added on top of valsartan after the first week of therapy with the angiotensin receptor blocker. Results. Serum creatinine increased in all three groups (mean change within a group: 11 μmol/l in group 1, P = 0.045; 9 μmol/l in group 2, P = 0.030; 15 μmol/l in group 3, P = 0.0006). Serum potassium also increased in all three groups of patients (mean change within a group: 0.28 mmol/l in group 1, P = 0.28; 0.48 mmol/l in group 2, P = 0.0008; 0.36 mmol/l in group 3, P = 0.02). After 5 weeks of treatment, the largest decrease in blood pressure was observed in group 3 (the mean change from baseline in seated diastolic blood pressure (SDBP) and seated systolic blood pressure (SSBP), respectively, were: -2.0 and -11.5 mmHg in group 1; -7.6 and -15.4 mmHg in group 2; -12.6 and -21.6 mmHg in group 3). In addition, both combination treatments resulted in the reduction of proteinuria. The total number of patients with adverse experiences were 10 (45.5%), 14 (33.3%) and 11 (25%) in groups 1, 2 and 3, respectively. In six patients (5.6%) therapy was discontinued as a result of adverse experiences. Only one patient in each of the combined therapy groups withdrew from the study because of hyperkalaemia and no patients were forced to withdraw because of an increase in serum creatinine, acute renal failure or hospitalization. Conclusions. These results indicate that short-term combination of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker is safe and well tolerated in patients with moderate chronic renal failure. (C) Lippincott Williams and Wilkins.

AB - Objective. Several experimental and clinical studies indicate that the renin system may play a pivotal role in progressing renal disease. The combination of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker could provide a higher degree of blockade of the renin-angiotensin system than either agent alone. Such enhanced suppression might be of benefit for patients exhibiting a progressive decline in renal function because of chronic renal disease. Methods. A pilot multinational, multicentre, randomized, active-controlled, parallel group open-label study has been conducted in a group of patients with progressive chronic renal failure (creatinine clearance 20-45 ml/min) either with or without proteinuria and hypertension. The primary aim of the study was to investigate the safety and tolerability of the combination of valsartan and benazepril. Patients were randomly assigned to one of three groups: group 1 received valsartan 160 mg once daily (n = 22); group 2 received valsartan 80 mg once daily plus benazepril 5 or 10 mg once daily (n = 42); group 3 received valsartan 160 mg once daily plus benazepril 5 or 10 mg once daily (n = 44). The study lasted for 5 weeks, and in groups 2 and 3 benazepril was added on top of valsartan after the first week of therapy with the angiotensin receptor blocker. Results. Serum creatinine increased in all three groups (mean change within a group: 11 μmol/l in group 1, P = 0.045; 9 μmol/l in group 2, P = 0.030; 15 μmol/l in group 3, P = 0.0006). Serum potassium also increased in all three groups of patients (mean change within a group: 0.28 mmol/l in group 1, P = 0.28; 0.48 mmol/l in group 2, P = 0.0008; 0.36 mmol/l in group 3, P = 0.02). After 5 weeks of treatment, the largest decrease in blood pressure was observed in group 3 (the mean change from baseline in seated diastolic blood pressure (SDBP) and seated systolic blood pressure (SSBP), respectively, were: -2.0 and -11.5 mmHg in group 1; -7.6 and -15.4 mmHg in group 2; -12.6 and -21.6 mmHg in group 3). In addition, both combination treatments resulted in the reduction of proteinuria. The total number of patients with adverse experiences were 10 (45.5%), 14 (33.3%) and 11 (25%) in groups 1, 2 and 3, respectively. In six patients (5.6%) therapy was discontinued as a result of adverse experiences. Only one patient in each of the combined therapy groups withdrew from the study because of hyperkalaemia and no patients were forced to withdraw because of an increase in serum creatinine, acute renal failure or hospitalization. Conclusions. These results indicate that short-term combination of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker is safe and well tolerated in patients with moderate chronic renal failure. (C) Lippincott Williams and Wilkins.

KW - Angiotensin converting enzyme inhibition

KW - Angiotensin type 1 receptor antagonists

KW - Benazepril

KW - Combination therapy

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=0033961438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033961438&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 89

EP - 95

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 1

ER -